Who we are
ABOUT MEDICINES FOR EUROPE
PURPOSE AND OBJECTIVES
OUR VALUES – OUR 5 PILLARS
STRUCTURE
MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
Key topics
COVID-19
ACCESS
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
EXTERNAL RESOURCES
FACTSHEETS
INFOGRAPHICS
PODCAST
POLICY
REPORTS
VIDEOS
Newsroom
IN THE NEWS
PRESS RELEASES
Contact us
Login
Generic medicines
Home
Medicines for Europe
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Medicines for Europe
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Positioning Statements on Physician-led Switching for Biosimilar Medicines
1 October 2021
Positioning statements on physician-led switching for biosimilar medicines (October 2021)
Biosimilar medicines group position on physician-led switching (July 2015)
Biosimilar medicines group position on biologic pharmacy substitution (September 2020)
Related Posts
EMA/HMA share definitive EU-wide position on biosimilar…
19 September 2022
The Biosimilar medicines group, a Medicines for Europe sector group,…
Medicines for Europe Position Paper on Bolar Exemption - Feb…
15 February 2021
Open
Medicines for Europe Position on IP Action Plan - March 2021
13 March 2021
Open
European patients need improved access to biosimilar…
22 April 2021
Fifteen years after the first global approval, biosimilar medicines systemically…
Medicines For Europe
Who we are
Key topics
Publications
Newsroom
Contact us
SECTOR GROUPS
Generic medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Biosimilar medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Value added medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
Events
Tweet
Tweet
Tweet
LinkedIn